RPGLIFE

RPG Life Sciences share price & financials

Price
₹2,859.8
Market cap
₹4.5k Cr
Sector
Healthcare
Calls analysed
3
Latest concall · Q4 FY26 · call held 30 Apr 2026

RPG Life Sciences Limited Q4 FY26

Revenue from Operations ₹176.9 cr +24%EBITDA ₹45.2 cr +48%EBITDA Margin 25.6%

What went well

  • Q4 FY26 Revenue from operations grew by 23.6% to INR 176.9 crores.
  • Q4 FY26 EBITDA grew by 48.0% to INR 45.2 crores, with margin improving from 21.4% to 25.6%.
  • Q4 FY26 PAT (excluding exceptional items) increased by 58.1%.

What to watch

  • API business was disrupted for a larger part of FY26 due to a fire incident, impacting overall FY26 growth.
  • International formulation segment performance was impacted by inventory rationalization by certain customers and regulatory delays in host countries.
Read the full call →

What RPG Life Sciences Limited does

RPG Life Sciences is an integrated research-based pharmaceutical company that develops, manufactures and markets branded formulations for the Indian and Nepal markets, oral solid generic and branded-generic formulations for regulated and emerging export markets, and high-value synthetic APIs. It operates three manufacturing facilities in Ankleshwar (Gujarat) and Navi Mumbai (Maharashtra) making formulations and APIs, supported by warehouses in Ankleshwar and Ghaziabad. Its Domestic Formulations business sells branded drugs to physicians across acute, chronic and specialty therapy areas, its International Formulations business exports generics and branded generics to over 50 countries, and its API business supplies niche synthetic APIs to global generic and pharma companies while also backward-integrating supply for its own formulations. The company holds a leadership position in the immunosuppressant segment both domestically and internationally, anchored by flagship product Azathioprine.

Segments

  • Domestic Formulations (DF)
  • International Formulations (IF)
  • APIs
Employees
1,300+
Manufacturing facilities
3 (2 formulation units in Ankleshwar, 1 API unit in Navi Mumbai)
Countries with market presence
50+
Market position
Leader in the immunosuppressant segment, domestic and international
Legacy "Textbook" brands
6
Therapy areas represented by high-equity brands
9
Headquarters Mumbai, MaharashtraEmployees 1,300 (FY26 (Apr 2026 investor ) Company website

Guidance record · Q4 FY26

what the last two calls moved 13 tracked 2 delivered 4 missed 7 open
  • API Plant Restoration delivered said Q4 FY25 Promised: Restoration by September/October, normalization from H2 FY26 Q4 FY26: The API segment demonstrated a strong recovery in Q4 with revenues of INR 33.3 crores (144% growth) and management confirmed margin stabilization has started, indicating the plant is fully operational and business normalized in H2 FY26 as targeted.
  • Domestic Market Value Growth missed said Q4 FY25 Promised: mid-teens for FY26 Q4 FY26: Full year FY26 domestic formulation growth was 13.7%. This is slightly below the 'mid-teens' (14-16%) guidance.
  • New API Molecules Pipeline on track said Q4 FY25 Promised: around 12 by end FY26 and FY27 Q4 FY26: Management confirmed the API pipeline has expanded to 13 products, aligning with the target of launching ~12 new molecules by the end of FY26/FY27.

All 13 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 16.0%, net profit up 19.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue172 173 143 169 182 +6%180 +4%177 +24%196 +16%
EBITDA46 49 25 35 39 −15%40 −18%33 +32%44 +26%
Net profit4 35 117 26 37 +825%22 −37%30 −74%31 +19%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +12.4% 1Y

₹2.0k₹2.5k₹3.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 17 Oct 2025Q4 FY26 — 30 Apr 2026

1Y: ₹2,401.6 on 10 Sept 2025 → ₹2,698.6. High ₹3,017.1 (20 Jul 2026), low ₹1,744 (23 Mar 2026).

How the price took the results

close before → close after

Q4 FY26
+13.0%
30 Apr
Q2 FY26
−1.2%
17 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 11.3% a year over 3 years, FY23 to FY26. Operating margin widened to 20.8%.

Year endingFY23FY24FY25FY26
Revenue₹513 Cr₹583 Cr₹653 Cr₹708 Cr
Operating profit₹103 Cr₹128 Cr₹159 Cr₹147 Cr
Operating margin20.1%22.0%24.3%20.8%
Interest₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹16 Cr₹16 Cr₹20 Cr₹21 Cr
Net profit₹67 Cr₹87 Cr₹183 Cr₹115 Cr
Net margin13.1%14.9%28.0%16.2%
Cash from operations₹91 Cr₹94 Cr₹78 Cr₹56 Cr
Free cash flow₹58 Cr₹25 Cr₹151 Cr₹-9 Cr
ROCE33.0%35.0%33.0%26.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹13 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr
Reserves₹203 Cr₹243 Cr₹294 Cr₹362 Cr₹541 Cr₹592 Cr
Borrowings₹2 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹20 Cr
Other liabilities₹85 Cr₹88 Cr₹112 Cr₹138 Cr₹152 Cr₹168 Cr
Total liabilities₹303 Cr₹345 Cr₹419 Cr₹513 Cr₹706 Cr₹793 Cr
Fixed assets₹113 Cr₹104 Cr₹124 Cr₹114 Cr₹179 Cr₹197 Cr
Capital work in progress₹12 Cr₹31 Cr₹25 Cr₹96 Cr₹27 Cr₹23 Cr
Investments₹0 Cr₹0 Cr₹58 Cr₹91 Cr₹93 Cr₹120 Cr
Other assets₹178 Cr₹210 Cr₹211 Cr₹212 Cr₹407 Cr₹454 Cr
Total assets₹303 Cr₹345 Cr₹419 Cr₹513 Cr₹706 Cr₹793 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs added +2.19 pp while the public trimmed −1.80 pp. The shareholder count shrank 8% to 23,886.

Promoters
73.0%
FIIs
0.9%
DIIs
8.7%
Public
17.4%

Since Jun 2025

  • DIIs +2.19 pp
  • Public −1.80 pp
  • FIIs −0.40 pp

How it drifted, 12 quarters

Over this window the public fell from 25.1% to 17.4% — −7.7 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 72.8%, FIIs 0.5%, DIIs 1.6%, Public 25.1%.Dec '23: Promoters 72.8%, FIIs 0.6%, DIIs 1.8%, Public 24.9%.Mar '24: Promoters 72.8%, FIIs 0.9%, DIIs 2.2%, Public 24.1%.Jun '24: Promoters 72.8%, FIIs 1.1%, DIIs 2.6%, Public 23.4%.Sep '24: Promoters 72.8%, FIIs 1.4%, DIIs 5.5%, Public 20.4%.Dec '24: Promoters 73.0%, FIIs 1.3%, DIIs 6.1%, Public 19.7%.Mar '25: Promoters 73.0%, FIIs 1.5%, DIIs 6.1%, Public 19.5%.Jun '25: Promoters 73.0%, FIIs 1.4%, DIIs 6.5%, Public 19.2%.Sep '25: Promoters 73.0%, FIIs 1.1%, DIIs 6.7%, Public 19.2%.Dec '25: Promoters 73.0%, FIIs 1.0%, DIIs 7.0%, Public 19.0%.Mar '26: Promoters 73.0%, FIIs 0.9%, DIIs 7.5%, Public 18.7%.Jun '26: Promoters 73.0%, FIIs 0.9%, DIIs 8.7%, Public 17.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of RPG Life Sciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Nucleus Life Trust (Mr. Harsh Vardhan Goenka is a Trustee) 53.94%unchanged
Ektara Enterprises LLP 15.57%unchanged
Clarus Capital I VC / PE5.59%+1.15 pp
Stel Holdings Limited 3.18%unchanged
Authum Investment & Infrastructure Lmited NBFC / DFI2.02%unchanged
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 1.10%unchanged
Harshvardhan Goenka 0.16%unchanged
Mala Goenka 0.05%unchanged
Carniwal Investment Limited 0.04%unchanged
Sofreal Mercantrade Pvt Ltd 0.00%unchanged
Malabar Coastal Holdings LLP 0.00%unchanged
Atlantus Dwellings and Infrastructure LLP 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Growth trap

To justify its price of ₹2699, this stock must grow earnings at 29% every year for 7 years. Our analysis caps realistic growth at ~10%. At that growth it is worth ₹1040 — downside of 61%.

Growth the price implies
28.6% a year
for 7 years, fading to 4%
It has actually compounded at
10.3% a year
net profit, FY23–FY26 · EPS 10.1%
The gap
0.2 pp
-61% downside if it only repeats history
Price today ₹2,698.6 Value at the reference growth ₹1,040.19

Change the assumptions yourself →

All earnings calls (3)

Read the Q4 FY26 call →

Learn to analyse RPG Life Sciences Limited

Guides on how to read this kind of business and the numbers that matter.